Patents by Inventor Bruce G. Szczepankiewicz

Bruce G. Szczepankiewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7238724
    Abstract: The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: July 3, 2007
    Assignee: Abbott Laboratories
    Inventors: David J. Madar, Stevan W. Djuric, Melissa J. Michmerhuizen, Hana A. Kopecka, Xiaofeng Li, Kenton L. Longenecker, Zhonghua Pei, Daisy Pireh, Hing L. Sham, Kent D. Stewart, Bruce G. Szczepankiewicz, Paul E. Wiedeman, Hong Yong
  • Patent number: 7208517
    Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, a method of antagonizing endothelin, methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: April 24, 2007
    Assignee: Abbott Labortories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King, Todd J. Janus, Robert J. Padley
  • Patent number: 7169797
    Abstract: The present invention is directed to compounds of formula (I), or a pharmaceutically suitable salt or prodrug thereof, which are useful for the selective inhibition of protein tyrosine phosphatase-1B (PTP1B), and are useful for the treatment of disorders caused by overexpressed or altered protein tyrosine phosphatase 1B.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: January 30, 2007
    Assignee: Abbott Laboratories
    Inventors: Zhili Xin, Gang Liu, Zhonghua Pei, Bruce G. Szczepankiewicz, Michael D. Serby, Hongyu Zhao
  • Patent number: 6972340
    Abstract: Compounds of formula (I) or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the compounds are disclosed.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: December 6, 2005
    Assignee: Abbott Laboratories
    Inventors: Gang Liu, Bruce G. Szczepankiewicz, Zhonghua Pei, Zhili Xin, David A. Janowick
  • Patent number: 6946481
    Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: September 20, 2005
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
  • Publication number: 20040259843
    Abstract: The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Application
    Filed: February 27, 2004
    Publication date: December 23, 2004
    Inventors: David J. Madar, Stevan W. Djuric, Melissa J. Michmerhuizen, Hana A. Kopecka, Xiaofeng Li, Kenton L. Longenecker, Zhonghua Pei, Daisy Pireh, Hing L. Sham, Kent D. Stewart, Bruce G. Szczepankiewicz, Paul E. Wiedeman, Hong Yong
  • Publication number: 20040214870
    Abstract: The present invention is directed to compounds of formula (I), 1
    Type: Application
    Filed: February 4, 2004
    Publication date: October 28, 2004
    Inventors: Zhili Xin, Gang Liu, Zhonghua Pei, Bruce G. Szczepankiewicz, Michael D. Serby, Hongyu Zhao
  • Publication number: 20040167188
    Abstract: The present invention is directed to compounds of formula (I), 1
    Type: Application
    Filed: February 14, 2003
    Publication date: August 26, 2004
    Inventors: Zhili Xin, Gang Liu, Zhonghua Pei, Bruce G. Szczepankiewicz, Michael D. Serby, Hongyu Zhao
  • Publication number: 20040121964
    Abstract: The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Application
    Filed: September 11, 2003
    Publication date: June 24, 2004
    Inventors: David J. Madar, Stevan W. Djuric, Melissa J. Feenstra, Hana A. Kopecka, Xiaofeng Li, Kenton L. Longenecker, ZhongHua Pei, Daisy Pireh, Hing L. Sham, Kent D. Stewart, Bruce G. Szczepankiewicz, Paul E. Wiedeman, Hong Yong
  • Patent number: 6693123
    Abstract: Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4—L6—C(W)—N(R5)—L5—, (e) —L4—L6—S(O)m—N(R5)—L5—, (f) —L4—N(R5)—C(W)—L7—L5—, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally subs
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: February 17, 2004
    Assignee: University of Pittsburgh
    Inventors: Said M. Sebti, Andrew D. Hamilton, David J. Augeri, Kenneth J. Barr, Greg B. Donner, Stephen A. Fakhoury, Stephen J. O'Connor, Saul H. Rosenberg, Wang Shen, Bruce G. Szczepankiewicz, Indrani W. Gunawardana
  • Publication number: 20020193596
    Abstract: Compounds having the formula 1
    Type: Application
    Filed: October 30, 2001
    Publication date: December 19, 2002
    Applicant: University of Pittsburgh
    Inventors: Said M. Sebti, Andrew D. Hamilton, David J. Augeri, Kenneth J. Barr, Greg B. Donner, Stephen A. Fakhoury, Stephen J. O'Connor, Saul H. Rosenberg, Wang Shen, Bruce G. Szczepankiewicz, Indrani W. Gunawardana
  • Publication number: 20020169157
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: February 27, 2002
    Publication date: November 14, 2002
    Inventors: Gang Liu, Zhili Xin, Zhonghua Pei, Xiaofeng Li, Bruce G. Szczepankiewicz, David A. Janowick, Thorsten K. Oost
  • Patent number: 6462194
    Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: May 15, 2000
    Date of Patent: October 8, 2002
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
  • Publication number: 20020072516
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: August 29, 2001
    Publication date: June 13, 2002
    Inventors: Gang Liu, Bruce G. Szczepankiewicz, Zhonghua Pei, Zhili Xin, David A. Janowick
  • Patent number: 6380241
    Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: April 30, 2002
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
  • Publication number: 20020035137
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: July 31, 2001
    Publication date: March 21, 2002
    Inventors: Gang Liu, Bruce G. Szczepankiewicz, Zhonghua Pei, Zhili Xin, Thorsten K. Oost, David A. Janowick
  • Patent number: 6162927
    Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: August 4, 1997
    Date of Patent: December 19, 2000
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King